23 results
Search Results
2. The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?
- Author
-
Coates, Laura C., Baraliakos, Xenofon, Blanco, Francisco J., Blanco‐Morales, Elena Alonso, Braun, Jurgen, Chandran, Vinod, Fernandez‐Sueiro, Jose Luis, FitzGerald, Oliver, Gallagher, Phil, Gladman, Dafna D., Gubar, Elena, Korotaeva, Tatiana, Loginova, Elena, Lubrano, Ennio, Mulero, Juan, Pinto‐Tasende, Jose, Queiro, Ruben, Sanz Sanz, Jesús, Szentpetery, Agnes, and Helliwell, Philip S.
- Subjects
SPONDYLOARTHROPATHIES ,HLA-B27 antigen ,ANKYLOSING spondylitis ,PSORIATIC arthritis ,MEDICAL radiography ,SACROILIAC joint ,RESEARCH ,PREDICTIVE tests ,CROSS-sectional method ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,RISK assessment ,SEVERITY of illness index ,COMPARATIVE studies ,PHENOTYPES - Abstract
Objective: To describe the radiographic phenotype of axial spondyloarthritis (SpA) according to the presence of HLA-B27.Methods: An international collaboration compared the radiographic phenotype of axial SpA according to HLA-B27 status. Patients with ankylosing spondylitis (AS) and axial psoriatic arthritis (PsA) were collected. Radiographs were read centrally, blinded to clinical details. The symmetry of the sacroiliac joints and lumbar syndesmophytes and the morphology of syndesmophytes (typical marginal versus atypical chunky), together with the modified Stoke Ankylosing Spondylitis Spine Score and the Psoriatic Arthritis Spondylitis Radiographic Index, were recorded.Results: A total of 244 patients with PsA and 198 patients with AS were included. In PsA, 60 patients (25%) were HLA-B27 positive while in AS, 148 patients (75%) were HLA-B27 positive. Patients with HLA-B27 were younger and more often male and had a longer duration of disease. In multivariable logistic regression, HLA-B27 was significantly associated with syndesmophyte symmetry (odds ratio [OR] 3.02 [95% confidence interval (95% CI) 1.38, 6.61]) and marginal syndesmophytes (OR 1.97 [95% CI 1.16, 3.36]) but not with sacroiliac symmetry. Mean radiographic scores were higher for patients with HLA-B27.Conclusion: Patients with axial SpA who are positive for HLA-B27 have more severe radiographic damage, more marginal syndesmophytes, and more frequent syndesmophyte symmetry compared to patients who are negative for HLA-B27. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.
- Author
-
Benkő, Z., Wright, A., Rehal, A., Cimpoca, B., Syngelaki, A., Delgado, J. L., Tsokaki, T., De Alvarado, M., Vojtassakova, D., Malligiannis Ntalianis, K., Chaveeva, P., Del Campo, A., De Ganzo, T., Resta, C., Atanasova, V., Accurti, V., Villalain, C., Aguilera, J., Dojcinovska, D., and O'Gorman, N.
- Subjects
PLACENTAL growth factor ,PREGNANCY ,PREECLAMPSIA ,UTERINE artery ,PREMATURE labor ,PREECLAMPSIA diagnosis ,ARTERIAL physiology ,PREGNANCY proteins ,RESEARCH ,PRENATAL diagnosis ,PREDICTIVE tests ,PHYSICS ,ARTERIES ,RESEARCH methodology ,GESTATIONAL age ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,HEMODYNAMICS ,MULTIPLE pregnancy ,BLOOD flow measurement ,LONGITUDINAL method - Abstract
Objectives: First, to validate a previously developed model for screening for pre-eclampsia (PE) by maternal characteristics and medical history in twin pregnancies; second, to compare the distributions of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum pregnancy-associated plasma protein-A (PAPP-A) in twin pregnancies that delivered with PE to those in singleton pregnancies and to develop new models based on these results; and, third, to examine the predictive performance of these models in screening for PE with delivery at < 32 and < 37 weeks' gestation.Methods: Two datasets of prospective non-intervention multicenter screening studies for PE in twin pregnancies at 11 + 0 to 13 + 6 weeks' gestation were used. The first dataset was from the EVENTS (Early vaginal progesterone for the preVention of spontaneous prEterm birth iN TwinS) trial and the second was from a previously reported study that examined the distributions of biomarkers in twin pregnancies. Maternal demographic characteristics and medical history from the EVENTS-trial dataset were used to assess the validity of risks from our previously developed model. The combined data from the first and second datasets were used to compare the distributional properties of log10 multiples of the median (MoM) values of UtA-PI, MAP, PlGF and PAPP-A in twin pregnancies that delivered with PE to those in singleton pregnancies and develop new models based on these results. The competing-risks model was used to estimate the individual patient-specific risks of delivery with PE at < 32 and < 37 weeks' gestation. Screening performance was measured by detection rates (DR) and areas under the receiver-operating-characteristics curve.Results: The EVENTS-trial dataset comprised 1798 pregnancies, including 168 (9.3%) that developed PE. In the validation of the prior model based on maternal characteristics and medical history, calibration plots demonstrated very good agreement between the predicted risks and the observed incidence of PE (calibration slope and intercept for PE < 32 weeks were 0.827 and 0.009, respectively, and for PE < 37 weeks they were 0.942 and -0.207, respectively). In the combined data, there were 3938 pregnancies, including 339 (8.6%) that developed PE and 253 (6.4%) that delivered with PE at < 37 weeks' gestation. In twin pregnancies that delivered with PE, MAP, UtA-PI and PlGF were, at earlier gestational ages, more discriminative than in singleton pregnancies and at later gestational ages they were less so. For PAPP-A, there was little difference between PE and unaffected pregnancies. The best performance of screening for PE was achieved by a combination of maternal factors, MAP, UtA-PI and PlGF. In screening by maternal factors alone, the DR, at a 10% false-positive rate, was 30.6% for delivery with PE at < 32 weeks' gestation and this increased to 86.4% when screening by the combined test; the respective values for PE < 37 weeks were 24.9% and 41.1%.Conclusions: In the assessment of risk for PE in twin pregnancy, we can use the same prior model based on maternal characteristics and medical history as reported previously, but in the calculation of posterior risks it is necessary to use the new distributions of log10 MoM values of UtA-PI, MAP and PlGF according to gestational age at delivery with PE. © 2020 International Society of Ultrasound in Obstetrics and Gynecology. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. Vessel morphology depicted by three-dimensional power Doppler ultrasound as second-stage test in adnexal tumors that are difficult to classify: prospective diagnostic accuracy study.
- Author
-
Sladkevicius, P., Jokubkiene, L., Timmerman, D., Fischerova, D., Van Holsbeke, C., Franchi, D., Savelli, L., Epstein, E., Fruscio, R., Kaijser, J., Czekierdowski, A., Guerriero, S., Pascual, M. A., Testa, A. C., Ameye, L., and Valentin, L.
- Subjects
ADNEXAL diseases ,DOPPLER ultrasonography ,OVARIAN tumors ,TUMORS ,DIAGNOSIS ,MORPHOLOGY ,RESEARCH ,THREE-dimensional imaging ,RESEARCH methodology ,ADENOMA ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,RECEIVER operating characteristic curves ,LONGITUDINAL method - Abstract
Objectives: To assess whether vessel morphology depicted by three-dimensional (3D) power Doppler ultrasound improves discrimination between benignity and malignancy if used as a second-stage test in adnexal masses that are difficult to classify.Methods: This was a prospective observational international multicenter diagnostic accuracy study. Consecutive patients with an adnexal mass underwent standardized transvaginal two-dimensional (2D) grayscale and color or power Doppler and 3D power Doppler ultrasound examination by an experienced examiner, and those with a 'difficult' tumor were included in the current analysis. A difficult tumor was defined as one in which the International Ovarian Tumor Analysis (IOTA) logistic regression model-1 (LR-1) yielded an ambiguous result (risk of malignancy, 8.3% to 25.5%), or as one in which the ultrasound examiner was uncertain regarding classification as benign or malignant when using subjective assessment. Even when the ultrasound examiner was uncertain, he/she was obliged to classify the tumor as most probably benign or most probably malignant. For each difficult tumor, one researcher created a 360° rotating 3D power Doppler image of the vessel tree in the whole tumor and another of the vessel tree in a 5-cm3 spherical volume selected from the most vascularized part of the tumor. Two other researchers, blinded to the patient's history, 2D ultrasound findings and histological diagnosis, independently described the vessel tree using predetermined vessel features. Their agreed classification was used. The reference standard was the histological diagnosis of the mass. The sensitivity of each test for discriminating between benign and malignant difficult tumors was plotted against 1 - specificity on a receiver-operating-characteristics diagram, and the test with the point furthest from the reference line was considered to have the best diagnostic ability.Results: Of 2403 women with an adnexal mass, 376 (16%) had a difficult mass. Ultrasound volumes were available for 138 of these cases. In 79/138 masses, the ultrasound examiner was uncertain about the diagnosis based on subjective assessment, in 87/138, IOTA LR-1 yielded an ambiguous result and, in 28/138, both methods gave an uncertain result. Of the masses, 38/138 (28%) were malignant. Among tumors that were difficult to classify as benign or malignant by subjective assessment, the vessel feature 'densely packed vessels' had the best discriminative ability (sensitivity 67% (18/27), specificity 83% (43/52)) and was slightly superior to subjective assessment (sensitivity 74% (20/27), specificity 60% (31/52)). In tumors in which IOTA LR-1 yielded an ambiguous result, subjective assessment (sensitivity 82% (14/17), specificity 79% (55/70)) was superior to the best vascular feature, i.e. changes in the diameter of vessels in the whole tumor volume (sensitivity 71% (12/17), specificity 69% (48/70)).Conclusion: Vessel morphology depicted by 3D power Doppler ultrasound may slightly improve discrimination between benign and malignant adnexal tumors that are difficult to classify by subjective ultrasound assessment. For tumors in which the IOTA LR-1 model yields an ambiguous result, subjective assessment is superior to vessel morphology as a second-stage test. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18.
- Author
-
Möckel, Martin, Boer, Rudolf A., Slagman, Anna Christine, Haehling, Stephan, Schou, Morten, Vollert, Jörn Ole, Wiemer, Jan C., Ebmeyer, Stefan, Martín‐Sánchez, F. Javier, Maisel, Alan S., Giannitsis, Evangelos, de Boer, Rudolf A, von Haehling, Stephan, and Martín-Sánchez, F Javier
- Subjects
CALCITONIN ,CLINICAL trials ,HEART failure ,NATRIURETIC peptides ,SYMPTOMS ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RANDOMIZED controlled trials - Abstract
Aim: To determine whether initiation of antibiotic therapy (ABX) by procalcitonin (PCT) within 8 h of admission in patients presenting to the emergency department with symptoms and signs of acute heart failure (AHF) and elevated natriuretic peptides would improve clinical outcomes.Methods and Results: The study was a randomized multicentre clinical trial conducted at 16 sites in Europe. Patients were randomized to either a PCT-guided strategy or standard care. Patients with PCT-guided strategy (n = 370) had ABX initiated if PCT was > 0.2 μg/L. Patients with standard care (n = 372) had AHF care in accordance with published guidelines without PCT. The primary endpoint was 90-day all-cause mortality. Pre-specified secondary endpoints included 30-day all-cause mortality and readmission and rate of pneumonia. The Data Safety and Review Committee recommended stopping the study for futility when 762 of the planned 792 patients had been enrolled. A total of 742 patients could be analysed. Patients were elderly (median age: 77 years), 38% were women, and had typical signs and symptoms of AHF. All-cause mortality at 90 days was 10.3% in the PCT-guided group vs. 8.2% in standard care (P = 0.316). Thirty-day readmission was significantly higher in the PCT-guided group vs. standard care but the difference vanished until day 90. The rate of pneumonia was overall low (7.5%) and not different between groups.Conclusions: In patients with AHF, a strategy of PCT-guided initiation of ABX was not more effective than a standard care strategy in improving clinical outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
6. Validation of ultrasound strategies to assess tumor extension and to predict high-risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)-4 cohort.
- Author
-
Verbakel, J. Y., Mascilini, F., Wynants, L., Fischerova, D., Testa, A. C., Franchi, D., Frühauf, F., Cibula, D., Lindqvist, P. G., Fruscio, R., Haak, L. A., Opolskiene, G., Alcazar, J. L., Mais, V., Carlson, J. W., Sladkevicius, P., Timmerman, D., Valentin, L., Bosch, T. Van Den, and Epstein, E.
- Subjects
ENDOMETRIAL cancer ,ENDOMETRIAL tumors ,TUMORS ,PREDICTION models ,MATHEMATICAL models ,DOPPLER ultrasonography ,RESEARCH ,RESEARCH evaluation ,ULTRASONIC imaging ,CANCER invasiveness ,RESEARCH methodology ,EVALUATION research ,BURDEN of care ,TUMOR classification ,COMPARATIVE studies ,RESEARCH funding ,SENSITIVITY & specificity (Statistics) ,LONGITUDINAL method - Abstract
Objectives: To compare the performance of ultrasound measurements and subjective ultrasound assessment (SA) in detecting deep myometrial invasion (MI) and cervical stromal invasion (CSI) in women with endometrial cancer, overall and according to whether they had low- or high-grade disease separately, and to validate published measurement cut-offs and prediction models to identify MI, CSI and high-risk disease (Grade-3 endometrioid or non-endometrioid cancer and/or deep MI and/or CSI).Methods: The study comprised 1538 patients with endometrial cancer from the International Endometrial Tumor Analysis (IETA)-4 prospective multicenter study, who underwent standardized expert transvaginal ultrasound examination. SA and ultrasound measurements were used to predict deep MI and CSI. We assessed the diagnostic accuracy of the tumor/uterine anteroposterior (AP) diameter ratio for detecting deep MI and that of the distance from the lower margin of the tumor to the outer cervical os (Dist-OCO) for detecting CSI. We also validated two two-step strategies for the prediction of high-risk cancer; in the first step, biopsy-confirmed Grade-3 endometrioid or mucinous or non-endometrioid cancers were classified as high-risk cancer, while the second step encompassed the application of a mathematical model to classify the remaining tumors. The 'subjective prediction model' included biopsy grade (Grade 1 vs Grade 2) and subjective assessment of deep MI or CSI (presence or absence) as variables, while the 'objective prediction model' included biopsy grade (Grade 1 vs Grade 2) and minimal tumor-free margin. The predictive performance of the two two-step strategies was compared with that of simply classifying patients as high risk if either deep MI or CSI was suspected based on SA or if biopsy showed Grade-3 endometrioid or mucinous or non-endometrioid histotype (i.e. combining SA with biopsy grade). Histological assessment from hysterectomy was considered the reference standard.Results: In 1275 patients with measurable lesions, the sensitivity and specificity of SA for detecting deep MI was 70% and 80%, respectively, in patients with a Grade-1 or -2 endometrioid or mucinous tumor vs 76% and 64% in patients with a Grade-3 endometrioid or mucinous or a non-endometrioid tumor. The corresponding values for the detection of CSI were 51% and 94% vs 50% and 91%. Tumor AP diameter and tumor/uterine AP diameter ratio showed the best performance for predicting deep MI (area under the receiver-operating characteristics curve (AUC) of 0.76 and 0.77, respectively), and Dist-OCO had the best performance for predicting CSI (AUC, 0.72). The proportion of patients classified correctly as having high-risk cancer was 80% when simply combining SA with biopsy grade vs 80% and 74% when using the subjective and objective two-step strategies, respectively. The subjective and objective models had an AUC of 0.76 and 0.75, respectively, when applied to Grade-1 and -2 endometrioid tumors.Conclusions: In the hands of experienced ultrasound examiners, SA was superior to ultrasound measurements for the prediction of deep MI and CSI of endometrial cancer, especially in patients with a Grade-1 or -2 tumor. The mathematical models for the prediction of high-risk cancer performed as expected. The best strategies for predicting high-risk endometrial cancer were combining SA with biopsy grade and the subjective two-step strategy, both having an accuracy of 80%. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.
- Author
-
Jones, Nicholas R., Roalfe, Andrea K., Adoki, Ibiye, Hobbs, F.D. Richard, and Taylor, Clare J.
- Subjects
META-analysis ,HEART failure patients ,MEDICAL protocols ,VENTRICULAR ejection fraction ,HEART failure treatment ,HEART ventricle diseases ,AGE factors in disease ,CHRONIC diseases ,COMPARATIVE studies ,HEALTH services accessibility ,LEFT heart ventricle ,HEART failure ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,SURVIVAL analysis (Biometry) ,COMORBIDITY ,EVALUATION research ,DISEASE progression ,STROKE volume (Cardiac output) - Abstract
Aim: To provide reliable survival estimates for people with chronic heart failure and explain variation in survival by key factors including age at diagnosis, left ventricular ejection fraction, decade of diagnosis, and study setting.Methods and Results: We searched in relevant databases from inception to August 2018 for non-interventional studies reporting survival rates for patients with chronic or stable heart failure in any ambulatory setting. Across the 60 included studies, there was survival data for 1.5 million people with heart failure. In our random effects meta-analyses the pooled survival rates at 1 month, 1, 2, 5 and 10 years were 95.7% (95% confidence interval 94.3-96.9), 86.5% (85.4-87.6), 72.6% (67.0-76.6), 56.7% (54.0-59.4) and 34.9% (24.0-46.8), respectively. The 5-year survival rates improved between 1970-1979 and 2000-2009 across healthcare settings, from 29.1% (25.5-32.7) to 59.7% (54.7-64.6). Increasing age at diagnosis was significantly associated with a reduced survival time. Mortality was lowest in studies conducted in secondary care, where there were higher reported prescribing rates of key heart failure medications. There was significant heterogeneity among the included studies in terms of heart failure diagnostic criteria, participant co-morbidities, and treatment rates.Conclusion: These results can inform health policy and individual patient advanced care planning. Mortality associated with chronic heart failure remains high despite steady improvements in survival. There remains significant scope to improve prognosis through greater implementation of evidence-based treatments. Further research exploring the barriers and facilitators to treatment is recommended. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
8. Navigating and making sense of urgent and emergency care processes and provision.
- Author
-
Pope, Catherine, McKenna, Gemma, Rogers, Anne, Turnbull, Joanne, and Prichard, Jane
- Subjects
COMPARATIVE studies ,EMERGENCY medical services ,ETHICS ,HELP-seeking behavior ,INTERVIEWING ,RESEARCH methodology ,MEDICAL needs assessment ,MEDICAL care use ,MEDICAL triage ,QUALITATIVE research ,JUDGMENT sampling ,NARRATIVES ,THEMATIC analysis ,PATIENT-centered care ,PATIENTS' attitudes - Abstract
Background: Whilst many health systems offer a range of urgent and emergency care services to deal with the need for unscheduled care, these can be problematic to navigate. Objective: To explore how lay people make sense of urgent care provision and processes. Design: Qualitative study, incorporating citizen panels and longitudinal semi‐structured qualitative interviews. Setting and Participants: Two citizens' panels, comprising purposively selected public populations—a group of regular users and a group of potentially marginalized users of urgent and emergency care. Semi‐structured interviews were conducted with 100 people, purposively sampled to include those over 75, aged 18‐26 years, and from East/Central Europe. A sub‐sample of 41 people received a second interview at +6‐12 months. Framework analysis was thematic and comparative, moving through coding to narrative and interpretive summaries. Findings and Discussion: Participants narratives illuminated considerable uncertainty and confusion regarding urgent and emergency care provision which in part could be traced to the contingent nature of urgent and emergency care need. Accounts of emergency care provision were underpinned by strong moral positioning of appropriate help‐seeking, demarcating legitimate service use that echoed policy rhetoric, but did not necessarily translate into individual behaviour. People struggled to make sense of urgent care provision making navigating "appropriate" use problematic. Conclusions: The focus on help‐seeking behaviour, rather than sense‐making, makes it difficult to move beyond the polarization of "appropriate" and "inappropriate" service use. A deeper analysis of sense‐making might shift the focus of attention and allow us to intervene to reshape understandings before this point. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.
- Author
-
Crespo‐Leiro, Maria G., Metra, Marco, Lund, Lars H., Milicic, Davor, Costanzo, Maria Rosa, Filippatos, Gerasimos, Gustafsson, Finn, Tsui, Steven, Barge‐Caballero, Eduardo, De Jonge, Nicolaas, Frigerio, Maria, Hamdan, Righab, Hasin, Tal, Hülsmann, Martin, Nalbantgil, Sanem, Potena, Luciano, Bauersachs, Johann, Gkouziouta, Aggeliki, Ruhparwar, Arjang, and Ristic, Arsen D.
- Subjects
HEART failure treatment ,TREATMENT effectiveness ,HEART transplantation ,OLDER people ,QUALITY of life ,CARDIOLOGY ,CARDIOVASCULAR disease diagnosis ,COMPARATIVE studies ,HEART failure ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL societies ,RESEARCH ,EVALUATION research ,HEART assist devices ,DIAGNOSIS - Abstract
This article updates the Heart Failure Association of the European Society of Cardiology (ESC) 2007 classification of advanced heart failure and describes new diagnostic and treatment options for these patients. Recognizing the patient with advanced heart failure is critical to facilitate timely referral to advanced heart failure centres. Unplanned visits for heart failure decompensation, malignant arrhythmias, co-morbidities, and the 2016 ESC guidelines criteria for the diagnosis of heart failure with preserved ejection fraction are included in this updated definition. Standard treatment is, by definition, insufficient in these patients. Inotropic therapy may be used as a bridge strategy, but it is only a palliative measure when used on its own, because of the lack of outcomes data. Major progress has occurred with short-term mechanical circulatory support devices for immediate management of cardiogenic shock and long-term mechanical circulatory support for either a bridge to transplantation or as destination therapy. Heart transplantation remains the treatment of choice for patients without contraindications. Some patients will not be candidates for advanced heart failure therapies. For these patients, who are often elderly with multiple co-morbidities, management of advanced heart failure to reduce symptoms and improve quality of life should be emphasized. Robust evidence from prospective studies is lacking for most therapies for advanced heart failure. There is an urgent need to develop evidence-based treatment algorithms to prolong life when possible and in accordance with patient preferences, increase life quality, and reduce the burden of hospitalization in this vulnerable patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II.
- Author
-
Linde, Cecilia M., Normand, Camilla, Bogale, Nigussie, Auricchio, Angelo, Sterlinski, Maciej, Marinskis, Germanas, Sticherling, Christian, Bulava, Alan, Pérez, Óscar Cano, Maass, Alexander H., Witte, Klaus K., Rekvava, Roin, Abdelali, Salima, and Dickstein, Kenneth
- Subjects
CARDIAC pacing ,ARRHYTHMIA treatment ,CARDIAC pacemakers ,HEART failure ,HEART disease diagnosis ,HEART failure treatment ,CARDIOLOGY ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL societies ,RESEARCH ,RESEARCH funding ,SURVIVAL ,EVALUATION research ,TREATMENT effectiveness ,DISEASE prevalence ,RETROSPECTIVE studies - Abstract
Background: To date, there are no data from randomized controlled studies on the benefit of cardiac resynchronization therapy (CRT) when implanted as an upgrade in patients with a previous device as compared to de novo CRT. In the CRT Survey II we compared the baseline data of patients upgraded to CRT (CRT-P/CRT-D) from a previous pacemaker (PM) or implantable cardioverter-defibrillator (ICD) to de novo CRT implantation.Methods and Results: In the European CRT Survey II, clinical practice data of patients undergoing CRT and/or ICD implantation across 42 European Society of Cardiology (ESC) countries were collected between October 2015 and December 2016. Out of a total of 11 088 patients, 2396 (23.2%) were upgraded from a previous PM or ICD and 7933 (76.8%) underwent de novo implantation. Compared to de novo implantations, upgraded patients were older, more often male, more frequently had ischaemic heart failure aetiology, atrial fibrillation, reduced renal function, worse heart failure symptoms, and higher N-terminal pro-B-type natriuretic peptide levels. Upgraded patients were more often PM-dependent and less frequently received CRT-D. Total peri-procedural, in-hospital complications and length of hospital stay were similar. Upgraded patients were less frequently treated with heart failure medication at discharge.Conclusion: Despite a lack of evidenced-based data, close to one quarter of all CRT implantations across 42 ESC countries were upgrades from a previous PM or ICD. Despite older age and worse symptoms, the CRT implantation procedures in upgraded patients were equally frequently successful and complications similar to de novo implantations. These results call for more studies. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how?
- Author
-
Dickstein, Kenneth, Normand, Camilla, Auricchio, Angelo, Bogale, Nigussie, Cleland, John G., Gitt, Anselm K., Stellbrink, Christoph, Anker, Stefan D., Filippatos, Gerasimos, Gasparini, Maurizio, Hindricks, Gerhard, Blomström Lundqvist, Carina, Ponikowski, Piotr, Ruschitzka, Frank, Botto, Giovanni Luca, Bulava, Alan, Duray, Gabor, Israel, Carsten, Leclercq, Christophe, and Margitfalvi, Peter
- Subjects
CARDIAC pacing ,CARDIAC pacemakers ,HEART failure ,HEART failure patients ,HEART failure treatment ,CARDIOLOGY ,COMPARATIVE studies ,DISEASES ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL protocols ,MEDICAL societies ,PROGNOSIS ,RESEARCH ,SURVIVAL ,EVALUATION research - Abstract
Background: Cardiac resynchronisation therapy (CRT) reduces morbidity and mortality in appropriately selected patients with heart failure and is strongly recommended for such patients by guidelines. A European Society of Cardiology (ESC) CRT survey conducted in 2008-2009 showed considerable variation in guideline adherence and large individual, national and regional differences in patient selection, implantation practice and follow-up. Accordingly, two ESC associations, the European Heart Rhythm Association and the Heart Failure Association, designed a second prospective survey to describe contemporary clinical practice regarding CRT.Methods and Results: A survey of the clinical practice of CRT-P and CRT-D implantation was conducted from October 2015 to December 2016 in 42 ESC member countries. Implanting centres provided information about their hospital and CRT service and were asked to complete a web-based case report form collecting information on patient characteristics, investigations, implantation procedures and complications during the index hospitalisation. The 11 088 patients enrolled represented 11% of the total number of expected implantations in participating countries during the survey period; 32% of patients were aged ≥75 years, 28% of procedures were upgrades from a permanent pacemaker or implantable cardioverter-defibrillator and 30% were CRT-P rather than CRT-D. Most patients (88%) had a QRS duration ≥130 ms, 73% had left bundle branch block and 26% were in atrial fibrillation at the time of implantation. Large geographical variations in clinical practice were observed.Conclusion: CRT Survey II provides a valuable source of information on contemporary clinical practice with respect to CRT implantation in a large sample of ESC member states. The survey permits assessment of guideline adherence and demonstrates variations in patient selection, management, implantation procedure and follow-up strategy. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
12. Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study.
- Author
-
Lund, Lars H., Trochu, Jean‐Noel, Meyns, Bart, Caliskan, Kadir, Shaw, Steven, Schmitto, Jan D., Schibilsky, David, Damme, Laura, Heatley, Jerry, Gustafsson, Finn, and Trochu, Jean-Noel
- Subjects
HEART failure treatment ,HEART transplantation ,HEART assist devices ,CARDIAC pacing ,VENTRICULAR ejection fraction ,COMPARATIVE studies ,HEART ventricles ,HEART failure ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,SURVIVAL ,EVALUATION research ,TREATMENT effectiveness - Abstract
Background: Heart transplantation (HTx) and implantable left ventricular assist systems (LVAS) improve outcomes in advanced heart failure but may be underutilized. We hypothesized that screening can identify appropriate candidates.Methods and Results: The ScrEEning for advanced Heart Failure treatment (SEE-HF) study was a multicentre prospective study screening patients with existing cardiac resynchronization therapy (CRT) and/or implantable cardioverter-defibrillator (ICD) for ejection fraction ≤40% and New York Heart Association (NYHA) class III-IV, and subsequently for guideline-based HTx and LVAS indication. Of 1722 (mean age 64 ± 14 years, 26% women) patients screened at eight centres in seven European countries, 121 (7.0%) were eligible and 99 (5.7%; mean age 61 ± 10 years, 19% women) patients were enrolled for detailed assessment. Twenty-six of the 99 enrolled patients (26%) were eligible for either HTx or LVAD (18 eligible for HTx; 7 eligible for LVAD; and 1 eligible for both). Eleven patients were listed for HTx and three received an LVAS. Eligible patients were 61 ± 8 years and 19% women, whereas those actually receiving intervention were 56 ± 8 years and 8% women.Conclusions: Among patients with CRT and/or ICD, a minority have NYHA class III-IV heart failure and ejection fraction ≤40%. Among these, however, more than one-quarter have an unrecognized need for HTx or LVAS. When patients are offered intervention based on screening, many decline. Discrepancies exist between clinical and patient equipoise. Clinical Trial Registration ClinicalTrials.gov Unique Identifier: NCT00894387. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
13. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
- Author
-
Canepa, Marco, Straburzynska‐Migaj, Ewa, Drozdz, Jaroslaw, Fernandez‐Vivancos, Carla, Pinilla, Jose Manuel Garcia, Nyolczas, Noemi, Temporelli, Pier Luigi, Mebazaa, Alexandre, Lainscak, Mitja, Laroche, Cécile, Maggioni, Aldo Pietro, Piepoli, Massimo F., Coats, Andrew J. S., Ferrari, Roberto, Tavazzi, Luigi, on behalf of the ESC‐HFA Heart Failure Long‐Term Registry Investigators, Straburzynska-Migaj, Ewa, Fernandez-Vivancos, Carla, and ESC-HFA Heart Failure Long-Term Registry Investigators
- Subjects
HEART failure ,OBSTRUCTIVE lung disease diagnosis ,CARDIOLOGY ,DISEASE prevalence ,ACE inhibitors ,PROGNOSIS ,ADRENERGIC beta blockers ,ALDOSTERONE antagonists ,COMPARATIVE studies ,HOSPITAL care ,LONGITUDINAL method ,OBSTRUCTIVE lung diseases ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL societies ,RESEARCH ,TIME ,COMORBIDITY ,EVALUATION research ,ACQUISITION of data ,THERAPEUTICS - Abstract
Aims: To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.Methods and Results: Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P < 0.001). At 1-year follow-up, the hazard ratios for COPD in multivariable analysis confirmed its independent association with hospitalizations both in HHF [all-cause: 1.16 (1.04-1.29), for HF: 1.22 (1.05-1.42)] and CHF patients [all-cause: 1.26 (1.13-1.41), for HF: 1.37 (1.17-1.60)]. The association between COPD and all-cause mortality was not confirmed in both groups after adjustments.Conclusions: COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial.
- Author
-
Mathur, Anthony, Arnold, Roman, Assmus, Birgit, Bartunek, Jozef, Belmans, Ann, Bönig, Halvard, Crea, Filippo, Dimmeler, Stefanie, Dowlut, Sheik, Fernández ‐ Avilés, Francisco, Galiñanes, Manuel, Garcia ‐ Dorado, David, Hartikainen, Juha, Hill, Jonathan, Hogardt ‐ Noll, Annette, Homsy, Christian, Janssens, Stefan, Kala, Petr, Kastrup, Jens, and Martin, John
- Subjects
BONE marrow cells ,MYOCARDIAL infarction ,VENTRICULAR ejection fraction ,REPERFUSION ,HEART failure ,PATIENTS ,HEART physiology ,LEFT heart ventricle ,BONE marrow transplantation ,CLINICAL trials ,COMPARATIVE studies ,CAUSES of death ,ECHOCARDIOGRAPHY ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,SURVIVAL ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness - Abstract
Over the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of BM-MNCs 2-8 days after successful reperfusion for AMI added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. Age-related reference values for the pediatric Scale for Assessment and Rating of Ataxia: a multicentre study.
- Author
-
Lawerman, Tjitske F, Brandsma, Rick, Burger, Huibert, Burgerhof, Johannes G M, and Sival, Deborah A
- Subjects
ATAXIA ,MOVEMENT disorders in children ,PEDIATRICS ,PEDIATRIC neurology ,JUVENILE diseases ,AGE distribution ,CHILD development ,COMPARATIVE studies ,GAIT in humans ,RESEARCH methodology ,MEDICAL cooperation ,REFERENCE values ,RESEARCH ,EVALUATION research ,RESEARCH bias ,SEVERITY of illness index ,DIAGNOSIS - Abstract
Copyright of Developmental Medicine & Child Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
16. Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study.
- Author
-
Desthieux, Carole, Granger, Benjamin, Balanescu, Andra Rodica, Balint, Peter, Braun, Jürgen, Canete, Juan D., Heiberg, Turid, Helliwell, Philip S., Kalyoncu, Umut, Kvien, Tore K., Kiltz, Uta, Niedermayer, Dora, Otsa, Kati, Scrivo, Rossana, Smolen, Josef, Stamm, Tanja A., Veale, Douglas J., de Vlam, Kurt, de Wit, Maarten, and Gossec, Laure
- Subjects
COMPARATIVE studies ,FUNCTIONAL assessment ,HEALTH attitudes ,HEALTH status indicators ,RESEARCH methodology ,MEDICAL cooperation ,MENTAL health ,PATIENT psychology ,PHYSICIANS ,PROGNOSIS ,RESEARCH ,RESEARCH evaluation ,PSORIATIC arthritis ,SELF-evaluation ,OCCUPATIONAL roles ,EVALUATION research ,PREDICTIVE tests ,RESEARCH bias ,DISEASE remission ,CROSS-sectional method ,SEVERITY of illness index ,PSYCHOLOGY ,DIAGNOSIS ,THERAPEUTICS - Abstract
Objective: Patient-physician discordance in global assessment of disease activity concerns one-third of patients, but what does it reflect? We aimed to assess patient-physician discordance in psoriatic arthritis (PsA) and patient-reported domains of health (physical and psychological) associated with discordance.Methods: We analyzed the PsAID (Psoriatic Arthritis Impact of Disease), a cross-sectional, multicenter European study of patients with PsA according to expert opinion. Patient global assessment (PGA) and physician global assessment (PhGA) were rated on a 0-10 numeric rating scale. Discordance was defined as the difference (PGA-PhGA) and as the absolute difference |PGA-PhGA| ≥3 points. Determinants of PGA-PhGA were assessed by a stepwise multivariate linear regression among 12 physical and psychological aspects of impact: pain, skin problems, fatigue, ability to work/leisure, functional incapacity, feeling of discomfort, sleep disturbance, anxiety/fear, coping, embarrassment/shame, social participation, and depressive affects.Results: In 460 patients (mean ± SD age 50.6 ± 12.9 years, 52.2% female, mean ± SD disease duration 9.5 ± 9.5 years, mean ± SD Disease Activity Index for Psoriatic Arthritis score 30.8 ± 32.4, and 40.4% undergoing treatment with biologic agents), the mean ± SD PGA was higher than the mean PhGA, with a mean absolute difference of 1.9 ± 1.8 points. Discordance defined by |PGA-PhGA| ≥3 of 10 concerned 134 patients (29.1%), and 115 patients (85.8% of the patients with discordance) had PGA>PhGA. Higher fatigue (β = 0.14), lower self-perceived coping (β = 0.23), and impaired social participation (β = 0.16) were independently associated with a higher difference (PGA-PhGA).Conclusion: Discordance concerned 29.1% of these patient/physician dyads, mainly by PGA>PhGA. Factors associated with discordance were psychological rather than physical domains of health. Discordance was more frequent in patients in remission, indicating more work is needed on the patient perspective regarding disease activity. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. Cross-Cultural and Construct Validity of the Animated Activity Questionnaire.
- Author
-
Peter, Wilfred F., de Vet, Henrika C. W., Boers, Maarten, Harlaar, Jaap, Roorda, Leo D., Poolman, Rudolf W., Scholtes, Vanessa A. B., Steultjens, Martijn, Hendry, Gordon J., Roos, Ewa M., Guillemin, Francis, Benedetti, Maria G., Cavazzuti, Lorenzo, Escobar, Antonio, Dagfinrud, Hanne, and Terwee, Caroline B.
- Subjects
OSTEOARTHRITIS diagnosis ,HIP joint diseases diagnosis ,COMPARATIVE studies ,FUNCTIONAL assessment ,HIP joint diseases ,KNEE diseases ,LANGUAGE & languages ,RESEARCH methodology ,MEDICAL cooperation ,OSTEOARTHRITIS ,QUESTIONNAIRES ,RESEARCH ,RESEARCH evaluation ,TRANSLATIONS ,ETHNOLOGY research ,EVALUATION research ,DIAGNOSIS - Abstract
Objective: The Animated Activity Questionnaire (AAQ) assesses activity limitations in patients with hip/knee osteoarthritis and consists of video animations; the patients choose the animation that best matches their own performance. The AAQ has shown good validity and reliability. This study aims to evaluate cross-cultural and construct validity of the AAQ.Methods: Cross-cultural validity was assessed using ordinal logistic regression analysis to evaluate differential item functioning (DIF) across 7 languages. Construct validity was assessed by testing correlations between the AAQ and a patient-reported outcome measure (PROM) and performance-based tests.Results: Data from 1,239 patients were available. Compared to the Dutch language (n = 279), none of the 17 items showed DIF in English (n = 202) or French (n = 193), 1 item showed uniform DIF in Spanish (n = 99) and Norwegian (n = 62), and 2 items showed uniform DIF in Danish (n = 201). In all these languages, the occurrence of DIF did not influence the total score, which remained comparable with the original Dutch version. For Italian (n = 203) versus Dutch, however, 6 items showed uniform DIF, and 1 item showed nonuniform DIF, indicating some problems with the cross-cultural validity between these countries. With regard to construct validity, the correlations with PROM (0.74) and performance-based tests (0.36-0.68) were partly as expected (>0.60).Conclusion: The AAQ, an innovative tool to measure activity limitations that can be placed on the continuum between PROMs and performance-based tests, showed a good overall cross-cultural validity, and seems to have great potential for international use in research and daily clinical practice in many European countries. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
18. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM.
- Author
-
Sliwa, Karen, Mebazaa, Alexandre, Hilfiker‐Kleiner, Denise, Petrie, Mark C., Maggioni, Aldo P., Laroche, Cecile, Regitz‐Zagrosek, Vera, Schaufelberger, Maria, Tavazzi, Luigi, van der Meer, Peter, Roos‐Hesselink, Jolien W., Seferovic, Petar, van Spandonck‐Zwarts, Karin, Mbakwem, Amam, Böhm, Michael, Mouquet, Frederic, Pieske, Burkert, Hall, Roger, Ponikowski, Piotre, and Bauersachs, Johann
- Subjects
PERIPARTUM cardiomyopathy ,CARDIOMYOPATHIES ,HEART failure ,ADRENERGIC beta blockers ,THERAPEUTIC embolization ,PATIENTS ,TREATMENT of cardiomyopathies ,CARDIOVASCULAR agents ,MEDICAL care cost statistics ,CHILDBIRTH ,CARDIOVASCULAR diseases in pregnancy ,COMPARATIVE studies ,DEMOGRAPHY ,ETHNIC groups ,RESEARCH methodology ,MEDICAL cooperation ,PUERPERAL disorders ,RESEARCH ,DISEASE management ,COMORBIDITY ,SOCIOECONOMIC factors ,EVALUATION research ,ACQUISITION of data ,DISEASE complications ,DIAGNOSIS ,THERAPEUTICS - Abstract
Aims: The purpose of this study is to describe disease presentation, co-morbidities, diagnosis and initial therapeutic management of patients with peripartum cardiomyopathy (PPCM) living in countries belonging to the European Society of Cardiology (ESC) vs. non-ESC countries.Methods and Results: Out of 500 patients with PPCM entered by 31 March 2016, we report on data of the first 411 patients with completed case record forms (from 43 countries) entered into this ongoing registry. There were marked differences in socio-demographic parameters such as Human Development Index, GINI index on inequality, and Health Expenditure in PPCM patients from ESC vs. non-ESC countries (P < 0.001 each). Ethnicity was Caucasian (34%), Black African (25.8%), Asian (21.8%), and Middle Eastern backgrounds (16.4%). Despite the huge disparities in socio-demographic factors and ethnic backgrounds, baseline characteristics are remarkably similar. Drug therapy initiated post-partum included ACE inhibitors/ARBs and mineralocorticoid receptor antagonists with identical frequencies in ESC vs. non-ESC countries. However, in non-ESC countries, there was significantly less use of beta-blockers (70.3% vs. 91.9%) and ivabradine (1.4% vs. 17.1%), but more use of diuretics (91.3% vs. 68.8%), digoxin (37.0% vs. 18.0%), and bromocriptine (32.6% vs. 7.1%) (P < 0.001). More patients in non-ESC vs. ESC countries continued to have symptomatic heart failure after 1 month (92.3% vs. 81.3%, P < 0.001). Venous thrombo-embolic events, arterial embolizations, and cerebrovascular accidents were documented in 28 of 411 patients (6.8%). Neonatal death rate was 3.1%.Conclusion: PPCM occurs in women from different ethnic backgrounds globally. Despite marked differences in socio-economic background, mode of presentation was largely similar. Embolic events and persistent heart failure were common within 1 month post-diagnosis and required intensive, multidisciplinary management. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
19. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
- Author
-
O'Gorman, N., Wright, D., Poon, L. C., Rolnik, D. L., Syngelaki, A., Wright, A., Akolekar, R., Cicero, S., Janga, D., Jani, J., Molina, F. S., de Paco Matallana, C., Papantoniou, N., Persico, N., Plasencia, W., Singh, M., and Nicolaides, K. H.
- Subjects
FIRST trimester of pregnancy ,PLACENTAL growth factor ,BAYES' theorem ,PREECLAMPSIA ,BLOOD proteins ,PRENATAL care ,UTERINE artery ,ARTERIAL physiology ,PREECLAMPSIA diagnosis ,COMPARATIVE studies ,GESTATIONAL age ,LONGITUDINAL method ,MATHEMATICAL models ,RESEARCH methodology ,MEDICAL cooperation ,PHYSICS ,PRENATAL diagnosis ,RESEARCH ,RISK assessment ,THEORY ,EVALUATION research - Abstract
Objective: To examine the diagnostic accuracy of a previously developed model for prediction of pre-eclampsia (PE) by a combination of maternal factors and biomarkers at 11-13 weeks' gestation.Methods: This was a prospective first-trimester multicenter study of screening for PE in 8775 singleton pregnancies. A previously published algorithm was used for the calculation of patient-specific risk of PE in each individual. The detection rates (DRs) and false-positive rates (FPRs) for delivery with PE < 32, < 37 and ≥ 37 weeks were estimated and compared with those for the dataset used for development of the algorithm.Results: In the study population, 239 (2.7%) cases developed PE, of which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed PE < 32, < 37 and ≥ 37 weeks, respectively. With combined screening by maternal factors, mean arterial pressure, uterine artery pulsatility index and serum placental growth factor, the DR was 100% (95% CI, 80-100%) for PE < 32 weeks, 75% (95% CI, 62-85%) for PE < 37 weeks and 43% (95% CI, 35-50%) for PE ≥ 37 weeks, at a 10% FPR. These DRs were similar to the estimated rates for the dataset used for development of the model: 89% (95% CI, 79-96%) for PE < 32 weeks, 75% (95% CI, 70-80%) for PE < 37 weeks and 47% (95% CI, 44-51%) for PE ≥ 37 weeks.Conclusion: Assessment of a combination of maternal factors and biomarkers at 11-13 weeks provides effective first-trimester screening for preterm PE. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
20. Natural history of 107 cases of fetal aortic stenosis from a European multicenter retrospective study.
- Author
-
Gardiner, H. M., Kovacevic, A., Tulzer, G., Sarkola, T., Herberg, U., Dangel, J., Öhman, A., Bartrons, J., Carvalho, J. S., Jicinska, H., Fesslova, V., Averiss, I., Mellander, M., Bulock, Frances, Shebani, Suhair, Clur, Sally Ann, Daehnert, Ingo, Salvo, Giovanni Di, Heying, Ruth, and Gewillig, Marc
- Subjects
AORTIC stenosis ,FETUS ,PERCUTANEOUS balloon valvuloplasty ,HYPOPLASTIC left heart syndrome ,PREGNANCY ,HEALTH ,CATHETERIZATION ,COMPARATIVE studies ,CORONARY circulation ,FETAL heart ,FETAL diseases ,FETAL ultrasonic imaging ,GESTATIONAL age ,RESEARCH methodology ,EVALUATION of medical care ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,RETROSPECTIVE studies - Abstract
Objectives: Fetal aortic valvuloplasty (FV) aims to prevent fetal aortic valve stenosis progressing into hypoplastic left heart syndrome (HLHS), which results in postnatal univentricular (UV) circulation. Despite increasing numbers of FVs performed worldwide, the natural history of the disease in fetal life remains poorly defined. The primary aim of this study was to describe the natural history of fetal aortic stenosis, and a secondary aim was to test previously published criteria designed to identify cases of emerging HLHS with the potential for a biventricular (BV) outcome after FV.Methods: From a European multicenter retrospective study of 214 fetuses with aortic stenosis (2005-2012), 107 fetuses in ongoing pregnancies that did not undergo FV were included in this study and their natural history was reported. We examined longitudinal changes in Z-scores of aortic and mitral valve and left ventricular dimensions and documented direction of flow across the foramen ovale and aortic arch, and mitral valve inflow pattern and any gestational changes. Data were used to identify fetuses satisfying the Boston criteria for emerging HLHS and estimate the proportion of these that would have been ideal FV candidates. We applied the threshold score whereby a score of 1 was assigned to fetuses for each Z-score meeting the following criteria: left ventricular length and width > 0; mitral valve diameter > -2; aortic valve diameter > -3.5; and pressure gradient across either the mitral or aortic valve > 20 mmHg. We compared the predicted circulation with known survival and final postnatal circulation (BV, UV or conversion from BV to UV).Results: Among the 107 ongoing pregnancies there were eight spontaneous fetal deaths and 99 livebirths. Five were lost to follow-up, five had comfort care and four had mild aortic stenosis not requiring intervention. There was intention-to-treat in these 85 newborns but five died prior to surgery, before circulation could be determined, and thus 80 underwent postnatal procedures with 44 BV, 29 UV and seven BV-to-UV circulatory outcomes. Of newborns with intention-to-treat, 69/85 (81%) survived ≥ 30 days. Survival at median 6 years was superior in cases with BV circulation (P = 0.041). Those with a postnatal UV circulation showed a trend towards smaller aortic valve diameters at first scan than did the BV cohort (P = 0.076), but aortic valve growth velocities were similar in both cohorts to term. In contrast, the mitral valve diameter was significantly smaller at first scan in those with postnatal UV outcomes (P = 0.004) and its growth velocity (P = 0.008), in common with the left ventricular inlet length (P = 0.004) and width (P = 0.002), were reduced significantly by term in fetuses with UV compared with BV outcome. Fetal data, recorded before 30 completed gestational weeks, from 70 treated neonates were evaluated to identify emerging HLHS. Forty-four had moderate or severe left ventricular depression and 38 of these had retrograde flow in the aortic arch and two had left-to-right flow at atrial level and reversed a-waves in the pulmonary veins. Thus 40 neonates met the criteria for emerging HLHS and BV circulation was documented in 13 (33%). Of these 40 cases, 12 (30%) had a threshold score of 4 or 5, of which five (42%) had BV circulation without fetal intervention.Conclusions: The natural history in our cohort of fetuses with aortic stenosis and known outcomes shows that a substantial proportion of fetuses meeting the criteria for emerging HLHS, with or without favorable selection criteria for FV, had a sustained BV circulation without fetal intervention. This indicates that further work is needed to refine the selection criteria to offer appropriate therapy to fetuses with aortic stenosis. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
21. Who, What, Where: an analysis of private sector family planning provision in 57 low- and middle-income countries.
- Author
-
Campbell, Oona M. R., Benova, Lenka, Macleod, David, Goodman, Catherine, Footman, Katharine, Pereira, Audrey L., and Lynch, Caroline A.
- Subjects
FAMILY planning ,LOW-income countries ,HEALTH surveys ,CONTRACEPTIVES ,SOCIOECONOMIC factors ,MEDICARE privatization ,BUSINESS ,COMPARATIVE studies ,CONTRACEPTION ,CONTRACEPTIVE drugs ,DEVELOPING countries ,INCOME ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,PRIVATE sector ,PUBLIC sector ,EVALUATION research ,ACCESS to information - Abstract
Objective: Family planning service delivery has been neglected; rigorous analyses of the patterns of contraceptive provision are needed to inform strategies to address this neglect.Methods: We used 57 nationally representative Demographic and Health Surveys in low- and middle-income countries (2000-2013) in four geographic regions to estimate need for contraceptive services, and examined the sector of provision, by women's socio-economic position. We also assessed method mix and whether women were informed of side effects.Results: Modern contraceptive use among women in need was lowest in sub-Saharan Africa (39%), with other regions ranging from 64% to 72%. The private sector share of the family planning market was 37-39% of users across the regions and 37% overall (median across countries: 41%). Private sector users accessed medical providers (range across regions: 30-60%, overall mean: 54% and median across countries 23%), specialised drug sellers (range across regions: 31-52%, overall mean: 36% and median across countries: 43%) and retailers (range across regions: 3-14%, overall mean: 6% and median across countries: 6%). Private retailers played a more important role in sub-Saharan Africa (14%) than in other regions (3-5%). NGOs and FBOs served a small percentage. Privileged women (richest wealth quintile, urban residents or secondary-/tertiary-level education) used private sector services more than the less privileged. Contraceptive method types with higher requirements (medical skills) for provision were less likely to be acquired from the private sector, while short-acting methods/injectables were more likely. The percentages of women informed of side effects varied by method and provider subtype, but within subtypes were higher among public than private medical providers for four of five methods assessed.Conclusion: Given the importance of private sector providers, we need to understand why women choose their services, what quality services the private sector provides, and how it can be improved. However, when prioritising one of the two sectors (public vs. private), it is critical to consider the potential impact on contraceptive prevalence and equity of met need. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
22. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York.
- Author
-
Cleland, J.G.F., Swedberg, K., Cohen-Solal, A., Cosin-Aguilar, J., Dietz, R., Follath, F., Gavazzi, A., Hobbs, R., Korewicki, J., Madeira, H.C., Preda, I., van Gilst, W.H., Widimsky, J., Mareev, V., Mason, J., Freemantle, N., Eastaugh, Joanne, Cleland, J G, and Eastaugh, J
- Subjects
HEART failure ,CARDIOVASCULAR diseases ,HEART failure treatment ,INTERNAL medicine ,GERIATRICS ,ACE inhibitors ,HEART ventricle diseases ,COMPARATIVE studies ,LEFT heart ventricle ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL quality control ,MEDICAL cooperation ,MEDICAL protocols ,RESEARCH ,SURVEYS ,EVALUATION research ,DISEASE complications - Abstract
Background: The EUROHEART programme is a rolling programme of cardiovascular surveys among the member nations of the European Society of Cardiology (ESC). These surveys will provide information on the nature of cardiovascular disease and its management. This manuscript describes a survey into the nature and management of heart failure.Aims: The EuroHeart Failure survey aims to describe the quality of hospital care, diagnostic and therapeutic, for patients with suspected or confirmed heart failure in ESC member countries. Patients will be interviewed subsequent to hospital discharge to assess their understanding of their condition, side effects from and their compliance with therapy and their satisfaction with the management for heart failure. The quality of management will be judged against the recommendations contained in the ESC guidelines on diagnosis and treatment of heart failure. Outcome will be further assessed by repeat interviews in 6-12 months time. A further survey of heart failure in 2001/2002 is also planned.Methods: A prospective survey of all deaths and discharges from medical (cardiology, internal medicine and geriatric medicine) and cardiac surgical wards to identify patients with heart failure, suspected or confirmed. Approximately 70 hospital clusters, comprising two to six hospitals in each cluster, in 24 member countries of the ESC are conducting the study. At the time of writing, approximately 30000 deaths and discharges have been screened and approximately 4000 patients have been enrolled.Conclusions: The EuroHeart Survey will allow actual practice to be compared to ESC guidelines on the diagnosis and treatment of heart failure. The surveys and guidelines should prove mutually informative. The main EuroHeart Failure project will be completed by late 2000. However, new centres volunteering to participate in the study (contact corresponding author) may be accepted providing they have the necessary research personnel and provided funding can be agreed for statistical support and administration. [ABSTRACT FROM AUTHOR]- Published
- 2000
23. Beyond parental control and authoritarian parenting style: understanding Chinese parenting through the cultural notion of training.
- Author
-
Chao, Ruth K. and Chao, R K
- Subjects
PARENTING ,PARENT-child relationships ,ADULT-child relationships ,CHILD rearing ,PARENTHOOD ,CHILD care ,COMPARATIVE studies ,CULTURE ,EMIGRATION & immigration ,LOCUS of control ,RESEARCH methodology ,MEDICAL cooperation ,PSYCHOLOGY of mothers ,PERSONALITY ,RESEARCH ,EVALUATION research ,EDUCATIONAL attainment - Abstract
This study addresses a paradox in the literature involving the parenting style of Asians: Chinese parenting has often been described as "controlling" or "authoritarian". These styles of parenting have been found to be predictive of poor school achievement among European-Americans, and yet the Chinese are performing quite well in school. This study suggests that the concepts of authoritative and authoritarian are somewhat ethnocentric and do not capture the important features of Chinese child rearing, especially for explaining their school success. Immigrant Chinese and European-American mothers of preschool-aged children were administered standard measures of parental control and authoritative-authoritarian parenting style as well as Chinese child-rearing items involving the concept of "training." After controlling for their education, and their scores on the standard measures, the Chinese mothers were found to score significantly higher on the "training" ideologies. This "training" concept has important features, beyond the authoritarian concept, that may explain Chinese school success. [ABSTRACT FROM AUTHOR]
- Published
- 1994
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.